New drug MT-303 takes on advanced liver cancer in first human trial
NCT ID NCT06478693
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a new drug called MT-303, alone or with two standard cancer drugs, in people with advanced liver cancer that has spread or cannot be removed. The main goals are to check safety, find the right dose, and see early signs of effectiveness. About 70 adults with a specific protein (GPC3) on their cancer cells will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MT-303 (a type of immunotherapy) alone or combined with atezolizumab and bevacizumab
What this could lead to
If it works, this could point toward a new treatment option for advanced liver cancer that has stopped responding to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 70 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects, and it is too soon to know if it will work.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cha University Bundang Medical Center
RECRUITINGGyeonggi-do, South Korea
Contact
-
Integrated Clinical Oncology Network (ICON) Pty Ltd
RECRUITINGWoolloongabba, Queensland, 4102, Australia
Contact
-
Linear Clinical Research
RECRUITINGMurdoch, Western Australia, 6150, Australia
Contact
-
National Taiwan University Hospital
RECRUITINGTaipei, Taiwan
Contact
-
Pusan National Univesity Hospital
RECRUITINGBusan, South Korea
Contact
-
Seoul National University Hospital
RECRUITINGSeoul, South Korea
Contact
-
St Vincent's Hospital
RECRUITINGSydney, New South Wales, 2010, Australia
Contact
-
Taipei Tzu Chi Hospital
RECRUITINGTaipei, Taiwan
Contact
-
The Alfred Hospital
RECRUITINGMelbourne, Victoria, 3004, Australia
Contact